Search results
We Think Shareholders May Want To Consider A Review Of Moderna, Inc.'s (NASDAQ:MRNA) CEO...
Simply Wall St. via Yahoo Finance· 3 days agoKey Insights Moderna to hold its Annual General Meeting on 6th of May CEO Stephane Bancel's total...
State’s highest paid CEO reports major drop in compensation - Boston Business Journal
The Business Journals· 7 days agoLast year, Douglas Ingram, the president and CEO of Sarepta Therapeutics (Nasdaq: SRPT), reported...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 22 hours agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
Moderna Inc (MRNA) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...
GuruFocus.com via Yahoo Finance· 1 hour agoAnd help us understand, as you've communicated with large retail pharmacy, how significant the PFS formulation is to them? A: (Stephane Bancel -
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via AOL· 11 hours agoThose products could range from RSV vaccines to individualized cancer treatments, which will help...
Moderna Inc (MRNA) Q1 2024 Earnings: Significant Revenue Decline Amid Strategic Shifts
GuruFocus.com via Yahoo Finance· 20 hours agoStrategic Developments and Future Outlook Moderna's CEO, Stephane Bancel, emphasized the company's...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 21 hours agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 22 hours agoModerna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 20 hours agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 14 hours agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.